Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Feb 25, 2025 · CIK: 1581178
Sentiment: neutral
Topics: sec-filing, 6-K, regulatory-update
TL;DR
Eupraxia Pharmaceuticals filed a 6-K on Feb 25, 2025, with a press release attached. Nothing major, just an update.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on February 25, 2025, reporting information for the month of February 2025. The filing includes a press release dated February 25, 2025, as Exhibit 99.1. The company is incorporated in A1 and its fiscal year ends on December 31.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' regulatory reporting, which is important for investors to stay informed about the company's ongoing compliance and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- Alex Rothwe (person) — Signatory for Eupraxia Pharmaceuticals Inc.
- February 25, 2025 (date) — Filing date and press release date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or that it has filed or is required to file with a stock exchange.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated February 25, 2025, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The company's principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is Eupraxia Pharmaceuticals Inc.'s telephone number?
The company's telephone number is (250) 590-3968.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
The filing indicates that Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 25, 2025 by Alex Rothwe regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).